Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Drug Discov Technol. 2013 Jun;10(2):155-9.

Network pharmacology: reigning in drug attrition?

Author information

1
Department of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R, HWCRC, Room 732, MI 48201, USA. mohammar@karmanos.org

Abstract

In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities) reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of disease, essentially reigning in the phenomenon of drug attrition.

PMID:
23237678
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Support Center